VanEck Vectors Morningstar Durable Dividend ETF DURA 深 沪
等待开盘 11-27 09:30:00 美东时间
34.2603
+0.200
+0.59%
华盛通- 最 高34.3252
- 今 开34.18
- 成交量 2930股
- 最 低 34.18
- 昨 收 34.06
- 总市值 4625.14万
- 52周最高 34.3252
- 市盈率 静 --
- 换手率 0.22%
- 52周最低 28.5889
- 委 比 0.00%
- 总股本 135.00万
- 历史最高 34.3252
- 量 比 0.56
- 振 幅 0.43%
- 历史最低 14.0328
- 每 手 1
- 风险率 1.01%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Endurance Technologies Schedules Q2FY26 Earnings Call
Endurance Technologies Ltd. ( ($IN:ENDURANCE) ) has issued an update. Endurance...
11-03 18:43
Endurance Technologies Announces Postal Ballot Results for Director Appointment
Endurance Technologies Ltd. ( ($IN:ENDURANCE) ) has shared an announcement. End...
10-15 18:52
EyePoint files automatic mixed securities shelf
EyePoint Pharmaceuticals (NASDAQ:EYPT) filed automatic mixed securities shelf. Filing More on EyePoint Pharmaceuticals EyePoint Pharmaceuticals, Inc. (EYPT) Presents At Citi's Biopharma Back To School...
10-15 04:27
EyePoint Pharmaceuticals Initiates Pivotal Phase 3 Program For DURAVYU To Treat Diabetic Macular Edema; Expects First Patient Dosage In Q1 2026
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with
10-15 04:03
Endurance Technologies Launches New Alloy Wheel Manufacturing Plant
Endurance Technologies Ltd. ( ($IN:ENDURANCE) ) has shared an update. Endurance...
10-11 14:52
宝理塑料集团推出DURAST(R)精细粉末化技术 实现高性能树脂粉末化
全球工程热塑性塑料领军企业宝理塑料集团宣布推出DURAST (R)精细粉末化技术，该技术可将高性能树脂转化为精细粉末，支持从原型制作到3D打印及大规模生产的多样...
09-26 17:02
HPQ Silicon Begins Production of Advanced Battery Cells
HPQ-Silicon Resources ( ($TSE:HPQ) ) has provided an update. HPQ Silicon Inc. h...
08-14 19:43
EyePoint Pharma Enrolls And Randomizes Over 400 Patients In Phase 3 LUGANO Pivotal Trial Of DURAVYU For Wet AMD Treatment
– Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest –– LUCIA pivotal Phase 3 trial continues rapid enrollment pace with 60% of patients
05-27 19:02
